Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MuSK-CAART

Cell therapy (CAR-T) · Kills target cells, directed at MuSK · developed by Cabaletta Bio

Phase 1 Most advanced trial (none active)

CABA Developer

1 Registered trials

What is MuSK-CAART?

MuSK-CAART is a CAR-T cell therapy targeting muscle-specific kinase (MuSK), a neuromuscular junction antigen. It is being studied in MuSK myasthenia gravis, an autoimmune disorder where antibodies attack the neuromuscular junction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Targets: MuSK (antigen)
Mechanism: Kills target cells, directed at MuSK
Therapy area: Oncology
Developer: Cabaletta Bio (CABA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05451212	Phase 1	MuSK Myasthenia Gravis	Completed	CABA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MuSK Myasthenia Gravis

Other drugs acting on MUSK

Adimanebart Phase 3

More from Cabaletta Bio

CABA-201 Phase 2/3 DSG3-CAART Phase 1/2

Sources

ClinicalTrials.gov NCT05451212

Updated Oct 3, 2026. Something wrong or missing? Report it on the CABA page.

Follow CABA, the company behind MuSK-CAART

See CABA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CABA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z